BS_NS7GSHB9
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 24.47437582128778
- age_years
- 10.263
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.544
- ANDROGEN_RESPONSE+0.459
- INTERFERON_ALPHA_RESPONSE+0.424
- CHOLESTEROL_HOMEOSTASIS+0.414
- MTORC1_SIGNALING+0.403
- INTERFERON_GAMMA_RESPONSE+0.392
- IL6_JAK_STAT3_SIGNALING+0.344
- OXIDATIVE_PHOSPHORYLATION+0.341
- UNFOLDED_PROTEIN_RESPONSE+0.320
- ANGIOGENESIS+0.315
Top 10 suppressed
- G2M_CHECKPOINT-0.258
- KRAS_SIGNALING_DN-0.184
- E2F_TARGETS-0.179
- MITOTIC_SPINDLE-0.131
- WNT_BETA_CATENIN_SIGNALING-0.127
- SPERMATOGENESIS-0.085
- NOTCH_SIGNALING-0.083
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.050
- HEDGEHOG_SIGNALING-0.002
- PANCREAS_BETA_CELLS+0.005
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_S1KK7XRH | low-grade glioma | — | 0.954 |
| 2 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.925 |
| 3 | BS_49852ZBH | pilocytic astrocytoma | — | 0.915 |
| 4 | BS_VARR255N | pilocytic astrocytoma | — | 0.913 |
| 5 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.912 |
| 6 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.909 |
| 7 | BS_9HSGV9TJ | pleomorphic xanthoastrocytoma(PXA) | — | 0.902 |
| 8 | BS_2KJ2YAZR | pilocytic astrocytoma | — | 0.900 |
| 9 | 62BFF895-C5CC-4F59-8348-2026B659FDF5 | — | — | 0.897 |
| 10 | BS_H1XPVS9A | low-grade glioma | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.544 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.459 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.424 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.414 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.403 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.392 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.344 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.341 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.315 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.307 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.304 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.298 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.289 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.272 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.263 | Inavolisib | — uncovered |
| APOPTOSIS | 0.262 | Idelalisib | — uncovered |
| COAGULATION | 0.258 | Binimetinib | — uncovered |